Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax, Inc. (NASDAQ:NVAX – Free Report) – Research analysts at Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for shares of Novavax in a note issued to investors on ...

Novavax (NVAX) is one of the stocks most watched by ... we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...

The consensus estimate for Novavax’s current full-year earnings is ($1.31) per share. Get Novavax alerts: Several other brokerages have also recently issued reports on NVAX. B. Riley reaffirmed ...

If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict. NasdaqGS:NVAX Earnings Per Share Growth February 4th 2025 Given this is a high-level ...

Bullish option flow detected in Novavax (NVAX) with 5,702 calls trading, 1.1x expected, and implied vol increasing almost 10 points to 99.21%.